SDMA

SKU: orb1299900

Description

Symmetric dimethylarginine (SDMA) is a key endogenous inhibitor of nitric oxide synthase (NOS), and its concentrations are notably elevated in end-stage renal disease (ESRD). This small molecule is utilized in research to investigate cardiovascular pathophysiology, renal function, and NOS regulation in both cellular and animal models.

Research Area

Immunology & Inflammation, Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 30344-00-4
• MW: 202.25
• Purity: 95.74% (May vary between batches)
• Formula: C₈H₁₈N₄O₂
• SMILES: CNC(NC)=NCCC[C@H](N)C(O)=O
• Target: Endogenous Metabolite,NO Synthase,NF-κB
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (9.89 mM);DMSO:50 mg/mL (247.22 mM)

Bioactivity

• In Vitro:
  SDMA inhibited dose dependently the NO synthesis in intact endothelial cells, whereas it had no effect on protein expression of NOS. This effect was associated with an increase in reactive oxygen species. Co-incubation with L-arginine but not D-arginine reversed the effect of SDMA on NOS pathway. Suggest that SDMA reduced the endothelial NO synthesis, probably by limiting L-arginine supply to NOS. It is concluded that SDMA might be a useful parameter for detecting patients in very early stages of chronic kidney disease and for determining their risk for developing cardiovascular disease.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Inhibitor, Human Endogenous Metabolite, Endogenous Metabolite, EndogenousMetabolite, inhibit, NG,NG'-Dimethyl-L-arginine, Symmetric dimethylarginine, SDMA

Compound Identifiers

PubChem CID

169148